Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 6/20 | 0.54 |
| ▸ | MMP2 | P08253 | 5/20 | 0.54 |
| ▸ | MMP8 | P22894 | 5/20 | 0.54 |
| ▸ | MMP13 | P45452 | 3/20 | 0.54 |
| ▸ | MMP10 | P09238 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245074 | 0.90 | ADAMTS5 (0.60) | MMP12MMP2MMP8ADAMTS5CTSB | |
| SCHEMBL2246984 | 0.88 | L3MBTL1 (0.60) | MMP12MMP2MMP8ADAMTS5CTSB | |
| SCHEMBL3582721 | 0.87 | HPGDS (0.61) | HPGDSMMP12MMP2MMP8MMP13 | |
| SCHEMBL2243898 | 0.86 | ADAMTS5 (0.53) | MMP12MMP2MMP8ADAMTS5ADAMTS4 | |
| SCHEMBL2252325 | 0.86 | ADAMTS5 (0.53) | MMP12MMP2MMP8MMP13ADAMTS5 | |
| SCHEMBL2248084 | 0.85 | HPGDS (0.57) | HPGDSMMP12MMP2MMP8MMP13 | |
| SCHEMBL2247683 | 0.85 | ADAMTS5 (0.58) | MMP12MMP2MMP8ADAMTS5ADAMTS4 | |
| SCHEMBL2248190 | 0.85 | ADAMTS5 (0.54) | MMP12MMP2MMP8ADAMTS5CTSB | |
| SCHEMBL2247076 | 0.85 | ADAMTS5 (0.68) | MMP12MMP2MMP8ADAMTS5ADAMTS4 | |
| SCHEMBL2246542 | 0.85 | TDP1 (0.56) | MMP12MMP2MMP8ADAMTS5ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | HPGDS 1417/4885MMP12 54/4885MMP2 49/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | HPGDS 1417/4885MMP12 54/4885MMP2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.